Oral iron supplementation with ferric maltol in patients with pulmonary hypertension

  1. Karen M Olsson1,2⇑,
  2. Jan Fuge1,2,
  3. Torben Brod1,
  4. Jan C Kamp1,
  5. Jan Schmitto3,
  6. Tibor Kempf4,
  7. Johann Bauersachs4 and
  8. Marius M Hoeper1,2
  1. 1Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
  2. 2German Centre of Lung Research (DZL), Hannover, Germany
  3. 3Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany
  4. 4Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany
  1. Karen M Olsson, MD, Department of Respiratory Medicine, Hannover Medical School, 30623 Hannover, Germany. E-mail: olsson.karen{at}mh-hannover.de

Footnotes

This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Conflict of interest: Dr. Olsson reports personal fees from Actelion, personal fees from MSD, personal fees from United Therapeutics, personal fees from Accleron, outside the submitted work.

Conflict of interest: Dr. Fuge has nothing to disclose.

Conflict of interest: Dr. Brod has nothing to disclose.

Conflict of interest: Dr. Kamp has nothing to disclose.

Conflict of interest: Dr. Schmitto reports personal fees and non-financial support from Medtronic, personal fees from Abbott, outside the submitted work.

Conflict of interest: Dr. Kempf reports personal fees from Vifor Pharma Ltd., personal fees from Pharmacosmos A/S, personal fees from Novartis, personal fees from AstraZeneca, outside the submitted work.

Conflict of interest: Dr. Bauersachs reports personal fees from Novartis, personal fees from BMS, personal fees from Pfizer, personal fees from Daichii, personal fees from Sankyo, grants and personal fees from Bayer, personal fees from Servier, grants and personal fees from CVRx, personal fees from MSD, personal fees from Boehringer Ingelheim, personal fees from AstraZeneca, grants and personal fees from Abiomed, personal fees from Abbott, grants and personal fees from Medtronic, grants and personal fees from Vifor, grants from Zoll, outside the submitted work.

Conflict of interest: Dr. Hoeper reports personal fees from Actelion, personal fees from Bayer, personal fees from MSD, personal fees from Pfizer, personal fees from Accleron, all outside the submitted work.

This is a PDF-only article. Please click on the PDF link above to read it.

  • Received March 10, 2020.
  • Accepted May 13, 2020.